BiotechTube
OnLume

OnLume

Madison, United States· Est.
onlume.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10.5M

Overview

OnLume is pioneering intraoperative fluorescence imaging to enhance the precision and outcomes of cancer surgeries. The company's core platform integrates specialized imaging hardware with targeted fluorescent agents to provide surgeons with real-time, high-contrast visualization of tumors and critical anatomy. Operating in the competitive but high-growth surgical guidance market, OnLume targets the significant unmet need for improved margin assessment and nerve sparing in procedures like breast cancer and prostatectomies. As a private, likely pre-revenue entity, its success hinges on clinical validation, regulatory clearance, and commercial execution in a capital-intensive medical device sector.

Oncology

Technology Platform

Fluorescence-guided surgery (FGS) imaging systems integrating specialized camera hardware and software with fluorescent contrast agents for real-time visualization of tumors and critical anatomy during surgery.

Funding History

2
Total raised:$10.5M
Series A$8M
Seed$2.5M

Opportunities

The global shift towards precision surgery and value-based healthcare creates a strong demand for technologies that improve surgical outcomes.
The growing incidence of cancer and the clinical need to reduce positive margin rates in surgeries like lumpectomy present a large and addressable market.
Potential for platform expansion into other surgical specialties beyond oncology, such as cardiovascular or reconstructive surgery.

Risk Factors

Intense competition from large, established medical device companies with extensive sales networks and integrated operating room ecosystems.
Regulatory pathway uncertainty and the high cost of clinical trials required to prove clinical utility and secure FDA clearance.
Challenges in achieving surgeon adoption and integrating new technology into established operating room workflows and budgets.

Competitive Landscape

OnLume competes in the surgical fluorescence imaging market against major players like Stryker (PINPOINT, SPY PHI), Zeiss (KINEVO, ORBEYE), Leica Microsystems, and Olympus. It also faces competition from other innovative startups such as Activ Surgical, SpectraWave, and Iveric Bio (formerly Ocuphire). Differentiation requires demonstrating superior image quality, quantification, workflow integration, or cost-effectiveness.

More companies in Digital Health & Biotech SaaS →More companies in United States →